Literature DB >> 23350534

Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes.

Guinevere Q Lee1, P Richard Harrigan, Winnie Dong, Art F Y Poon, Jayvant Heera, James Demarest, Alex Rinehart, Doug Chapman, Hernan Valdez, Simon Portsmouth.   

Abstract

HIV-1 tropism can be predicted using V3 genotypic algorithms. The performance of these prediction algorithms for non-B subtypes is poorly characterized. Here, we use these genotypic algorithms to predict viral tropism of HIV-1 subtype A, B, C, and D to find apparent sensitivity, specificity, and concordance against a recombinant phenotypic assay, the original Trofile assay. This is a substudy of an epidemiological study (Pfizer A4001064). Plasma samples were selected to represent a large number of DM/X4 and R5 viruses. The HIV-1 env gene V3 loop was genotyped by Sanger sequencing (N=260) or 454 "deep" sequencing (N=280). Sequences were scored with g2p[coreceptor], PSSM X4/R5, PSSM SI/NSI, and PSSM subtype C matrices. Overall, non-B subtypes tropism prediction had similar concordance and apparent sensitivity and specificity as subtype B in predicting Trofile's results in both population sequencing (81.3%, 65.6%, and 90.5% versus 84.2%, 78.5%, and 88.2%) and 454 "deep" sequencing (82.3%, 80.0%, and 83.6% versus 86.8%, 92.0%, and 82.6%) using g2p[coreceptor]. By population sequencing, subtype A had lower sensitivity, whereas subtype D had lower specificity for non-R5 predictions, both in comparison to subtype B. 454 "deep" sequencing improved subtype A sensitivity but not subtype D. Subtype C had greater concordance than subtype B regardless of sequencing methods. In conclusion, genotypic tropism prediction algorithms may be applied to non-B HIV-1 subtypes with caution. Collective analysis of non-B subtypes revealed a performance similar to subtype B, whereas a subtype-specific analysis revealed overestimation (subtype D) or underestimation (subtype A).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23350534      PMCID: PMC3653393          DOI: 10.1089/aid.2012.0338

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  14 in total

1.  Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.

Authors:  Rachel A McGovern; Alexander Thielen; Theresa Mo; Winnie Dong; Conan K Woods; Douglass Chapman; Marilyn Lewis; Ian James; Jayvant Heera; Hernan Valdez; P Richard Harrigan
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

2.  Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

Authors:  Gerd Fätkenheuer; Anton L Pozniak; Margaret A Johnson; Andreas Plettenberg; Schlomo Staszewski; Andy I M Hoepelman; Michael S Saag; Frank D Goebel; Jürgen K Rockstroh; Bruce J Dezube; Tim M Jenkins; Christine Medhurst; John F Sullivan; Caroline Ridgway; Samantha Abel; Ian T James; Mike Youle; Elna van der Ryst
Journal:  Nat Med       Date:  2005-10-05       Impact factor: 53.440

3.  A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.

Authors:  Mark A Jensen; Mia Coetzer; Angélique B van 't Wout; Lynn Morris; James I Mullins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

Authors:  Rachel A McGovern; Alexander Thielen; Simon Portsmouth; Theresa Mo; Winnie Dong; Conan K Woods; Xiaoyin Zhong; Chanson J Brumme; Douglass Chapman; Marilyn Lewis; Ian James; Jayvant Heera; Hernan Valdez; P Richard Harrigan
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

5.  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Authors:  Patrick Dorr; Mike Westby; Susan Dobbs; Paul Griffin; Becky Irvine; Malcolm Macartney; Julie Mori; Graham Rickett; Caroline Smith-Burchnell; Carolyn Napier; Rob Webster; Duncan Armour; David Price; Blanda Stammen; Anthony Wood; Manos Perros
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses.

Authors:  Stéphanie Raymond; Pierre Delobel; Maud Mavigner; Laurent Ferradini; Michelle Cazabat; Corinne Souyris; Karine Sandres-Sauné; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

7.  Predicting HIV coreceptor usage on the basis of genetic and clinical covariates.

Authors:  Tobias Sing; Andrew J Low; Niko Beerenwinkel; Oliver Sander; Peter K Cheung; Francisco S Domingues; Joachim Büch; Martin Däumer; Rolf Kaiser; Thomas Lengauer; P Richard Harrigan
Journal:  Antivir Ther       Date:  2007

8.  Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.

Authors:  Wei Huang; Susan H Eshleman; Jonathan Toma; Signe Fransen; Eric Stawiski; Ellen E Paxinos; Jeannette M Whitcomb; Alicia M Young; Deborah Donnell; Francis Mmiro; Philippa Musoke; Laura A Guay; J Brooks Jackson; Neil T Parkin; Christos J Petropoulos
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

9.  Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.

Authors:  Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Authors:  Gerd Fätkenheuer; Mark Nelson; Adriano Lazzarin; Irina Konourina; Andy I M Hoepelman; Harry Lampiris; Bernard Hirschel; Pablo Tebas; François Raffi; Benoit Trottier; Nicholaos Bellos; Michael Saag; David A Cooper; Mike Westby; Margaret Tawadrous; John F Sullivan; Caroline Ridgway; Michael W Dunne; Steve Felstead; Howard Mayer; Elna van der Ryst
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 176.079

View more
  11 in total

1.  Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda.

Authors:  Guinevere Q Lee; Chris Lachowski; Eric Cai; Viviane D Lima; Yap Boum; Conrad Muzoora; Adrienne Rain Mocello; Peter W Hunt; Jeffrey N Martin; David R Bangsberg; P Richard Harrigan
Journal:  AIDS       Date:  2016-07-17       Impact factor: 4.177

2.  Time-Limited Trials in the Intensive Care Unit to Promote Goal-Concordant Patient Care.

Authors:  Todd D VanKerkhoff; Elizabeth M Viglianti; Michael E Detsky; Jacqueline M Kruser
Journal:  Clin Pulm Med       Date:  2019-09

3.  Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

Authors:  Richard M Gibson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

Review 4.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

5.  Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.

Authors:  Ron M Kagan; Erik P Johnson; Martin F Siaw; Ben Van Baelen; Richard Ogden; Jamie L Platt; Rick L Pesano; Eric Lefebvre
Journal:  AIDS Res Hum Retroviruses       Date:  2013-08-14       Impact factor: 2.205

6.  The temporal increase in HIV-1 non-R5 tropism frequency among newly diagnosed patients from northern Poland is associated with clustered transmissions.

Authors:  Miłosz Parczewski; Magdalena Leszczyszyn-Pynka; Magdalena Witak-Jędra; Katarzyna Maciejewska; Sławomira Myślińska; Anna Urbańska
Journal:  J Int AIDS Soc       Date:  2015-08-20       Impact factor: 5.396

7.  A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.

Authors:  Daniele Armenia; Cathia Soulie; Domenico Di Carlo; Lavinia Fabeni; Caterina Gori; Federica Forbici; Valentina Svicher; Ada Bertoli; Loredana Sarmati; Massimo Giuliani; Alessandra Latini; Evangelo Boumis; Mauro Zaccarelli; Rita Bellagamba; Massimo Andreoni; Anne-Geneviève Marcelin; Vincent Calvez; Andrea Antinori; Francesca Ceccherini-Silberstein; Carlo-Federico Perno; Maria Mercedes Santoro
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

8.  Reliable genotypic tropism tests for the major HIV-1 subtypes.

Authors:  Kieran Cashin; Lachlan R Gray; Katherine L Harvey; Danielle Perez-Bercoff; Guinevere Q Lee; Jasminka Sterjovski; Michael Roche; James F Demarest; Fraser Drummond; P Richard Harrigan; Melissa J Churchill; Paul R Gorry
Journal:  Sci Rep       Date:  2015-02-25       Impact factor: 4.379

9.  Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.

Authors:  Richard M Gibson; Ashley M Meyer; Dane Winner; John Archer; Felix Feyertag; Ezequiel Ruiz-Mateos; Manuel Leal; David L Robertson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

10.  Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism.

Authors:  Nicolas Jeanne; Adrien Saliou; Romain Carcenac; Caroline Lefebvre; Martine Dubois; Michelle Cazabat; Florence Nicot; Claire Loiseau; Stéphanie Raymond; Jacques Izopet; Pierre Delobel
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.